ELKE DR. HELLWEGE,WOLFRAM DR. ANDERSCH,KLAUS DR. STENZEL,BERND DR. SPRINGER
申请号：
ARP130101882
公开号：
AR091816A1
申请日:
2013.05.29
申请国别(地区):
AR
年份:
2015
代理人:
摘要：
Claim 1: a composition which comprises at least a Biological control Agent selected from the group consisting of Bacillus chitinosporus aq746 (Access no. NRRL B - 21618), Bacillus mycoides (no access aq726 NRRL B - 21664), Bacillus pumilus (Access no. 30087 NRRL B -) Bacillus Aq717 pumilus (Access no. NRRL B - 21662), Bacillus sp. aq175 (ATCC no. Access 55608), Bacillus sp.Aq177 (ATCC no. Access 35653), Bacillus sp.Aq178 (ATCC no. Access 53522), Bacillus subtilis (no access aq743 NRRL B - 21665), Bacillus subtilis (no access aq713 NRRL B - 21661), Bacillus subtilis (ATCC no. aq153 Access 55614 Bacillus thuringiensis), BD (Access no. 32 # NRRL B - aq52 21530), Bacillus thuringiensis Access NRR (no. L B - 21619 muscodor albus), 620 (no. Access NRRL 30547 muscodor roseus), A3 - 5 (no access 30548 NRRL)Rhodococcus globerulus aq719 (Access no. NRRL B - 21663), Streptomyces galbus (NRRL 30232 Access Number (no.), Streptomyces sp. NRRL B - Access 30145), Bacillus thuringiensis subspec.Kurstaki BMP aq30002 (no. 123, Bacillus subtilis NRRL B - Access 50421) and Bacillus subtilis (no access aq30004 NRRL B -.), and / or a Mutant of these strains having all the identifying characteristics of the respective Strain, and / or a metabolite produced by the respective strain that displays And activity against insects, mites,Plant pathogens and nematodes and / or at least one selected from the group consisting of Insect nicotinic acetylcholine receptor agonists (ncahr) and allosteric activators of the nicotinic acetylcholine receptor (nAChR) in a synergistically effective amount.Claim 2: the composition according to claim 1, wherein the agonist acetylcholine nicotinic receptor (nAChR) is selected from the group consisting of neonicotinoids, Nicotine and sulfoxaflor, and / or the allosteric Activator of the nicotinic acetylcholine receptor (nach R) is a spinosyn.Claim 3: the composition according to claim 2, wherein the agonist acetylcholine nicotinic receptor (nAChR) is selected f
